Marchini et al. (38) reported that in patients with severe AS undergoing TAVR, circulating EV levels, including endothelial- (Annexin V+/CD31+), platelet- (Annexin V+/CD41+), and macrophage-derived (Annexin V+/CD45+) vesicles, remained unchanged five days post-procedure, suggesting that EV concentrations remain stable in the early post-TAVR phase and that longer follow-up may be required to observe significant reductions [38]. This evidence concerns the gene ANXA5 and aortic stenosis.